A Novel Lair-1 Antibody Selectively Targets Acute Myeloid Leukemia (AML) Stem Cells

干细胞 癌症研究 髓系白血病 白血病 医学 免疫学 移植 生物 内科学 遗传学
作者
Linjie Tian,Ana Paucarmayta,Rustin R. Lovewell,Karla Maloveste,Junshik Hong,Carly Hedgepath,Kwang Woon Kim,Ron Copeland,Thomas O’Neill,Shashank J. Patel,Linda N. Liu,Han Myint,Solomon Langermann,Dallas B. Flies,Tae Kon Kim
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 3413-3413 被引量:2
标识
DOI:10.1182/blood-2021-147656
摘要

Abstract Extensive research has led to recent approval of novel therapies such as mylotarg, venetoclax, glasdegib and CC486, and small molecule inhibitors against actionable mutations such as ivosidenib (IDH1), enasidenib (IDH2), gliteritinib and midostaurin (FLT3) in AML. However, the mainstay of treatment in AML remains unchanged since the 1970s. There is a significant unmet need for AML patients that fail to respond to or relapse after standard-of-care (SOC) treatments including allogeneic stem cell transplantation and targeting actionable mutations. In addition, a large fraction of SOC patients invariably relapse due to persistence of chemotherapy-resistant leukemia stem cells (LSCs) or immune evasion. Therefore, identification of unique therapies that preferentially target elusive LSCs and promote immune responses to AML to prevent relapse are highly sought after. Unlike, targeting acute lymphoblastic leukemia (ALL) with CD19 or CD22 with various modalities, when developing AML therapies, it is of paramount importance to differentiate LSCs from hematopoietic stem cells (HSCs) to lessen or abolish unavoidable cytopenias. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) is an immune checkpoint receptor on T cells and myeloid cells that delimits immune cell activation through binding to endogenous collagen ligands. In addition, LAIR-1 is universally expressed on AML blasts and may sustain AML survival signals. We demonstrated using multi-color flow cytometry that LAIR-1 is highly expressed in AML blasts (n=9 of 9) and that LAIR-1 expression in LSCs (markers: CD34 +CD38 -CD90 -CD45RA +/- or CD34 -CD117 +CD244 +/-) is high compared with negligible expression of LAIR-1 in HSCs (markers: CD34 +CD38 -CD90 +CD99 -) (n=3) (Figure 1). Based on these findings, we hypothesized that a LAIR-1 monoclonal antibody (mAb) would disrupt LAIR-1 mediated survival signaling and preferentially target LAIR-1 expressing AML LSCs and blast cells but not HSCs. To test this, we developed a novel LAIR-1 targeting mAb with a functional human IgG 1 isotype that blocks LAIR-1 binding to its ligands (including collagens, complement component C1q, MBL and SP-D) To characterize the anti-leukemic effect of the LAIR-1 mAb we performed an in vitro antibody dependent cell cytotoxicity (ADCC) assay with LAIR-1 expressing AML cells (MOLT4 and MV-4-11). Compared with isotype control, the LAIR-1 mAb significantly increased leukemia cell death (MV411 = 17% above isotype, and MOLT4 = 29.24% above isotype at 15 µg/ml), suggesting that the LAIR-1 mAb confers ADCC activity against LAIR1 + AML cells (Figure 2). To elucidate if the LAIR-1 mAb has a direct signaling effect on LAIR-1 + AML cells, a colony forming unit assay using primary AML cells was carried out. Interestingly, the LAIR-1 mAb inhibited colony formation by AML CD34 + cells (40-60% decreased compared with isotype control, N=4), but not normal CD34 + cells. These data suggests that our LAIR-1 mAb stimulated LAIR-1 signaling that inhibits LSC self-renewal. We then tested the in vivo anti-leukemia effect of the mAb in cell line derived xenograft (CDX) models (immune deficient mice transplanted with MV-4-11 expressing luciferase). In vivo bioluminescence imaging indicated that the LAIR-1 mAb significantly inhibited in vivo AML growth (91% reduction of total flux)(Figure 3). A significant increase in cell death was observed in the presence of the mAb in the blood (47%), spleen (89.4%) and bone marrow (27.6%). Similar to the anti-leukemic effect in CDX AML models, the LAIR-1 mAb significantly suppressed in vivo growth of AML patient derived xenografts (5 different primary AML donors) (10-90% human CD33 + AML cells in isotype control treatment vs 0.5-5% CD33 + AML cells in anti-LAIR-1 treatment, N=3) (Figure 4), while minimally impacting normal immune cells. Taken together, our studies suggest that the LAIR-1 mAb we generated is a novel AML immunomedicine that preferentially eradicates AML LSCs and blasts while preserving healthy HSCs through disruption of AML survival signals and clearance of AML through ADCP and ADCC. Additional studies are currently evaluating if this novel LAIR-1 mAb has other mechanisms of action that contribute to overall in vivo activity, including reduction of AML niche implantation, regulation of bone marrow homing and regulation of anti-tumor immunity. Figure 1 Figure 1. Disclosures Tian: NextCure: Ended employment in the past 24 months. Paucarmayta: NextCure: Current Employment. Lovewell: NextCure: Current Employment. Maloveste: NextCure: Current Employment. Copeland: NextCure: Current Employment. O'Neill: NextCure: Current Employment. Patel: NextCure: Current Employment. Liu: NextCure: Current Employment, Current holder of stock options in a privately-held company. Myint: NextCure: Current Employment, Current holder of stock options in a privately-held company. Langermann: NextCure: Current Employment, Current holder of stock options in a privately-held company. Flies: NextCure: Current Employment, Current holder of stock options in a privately-held company. Kim: Nextcure: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
t铁核桃1985完成签到 ,获得积分0
1秒前
maomao完成签到 ,获得积分10
3秒前
tyuuoooo完成签到 ,获得积分10
3秒前
7秒前
涩费爱完成签到 ,获得积分10
8秒前
研友_n0kjPL完成签到,获得积分0
9秒前
忧伤的白秋完成签到,获得积分10
10秒前
fantasy的应助被369ninja采纳,获得10
13秒前
清洋完成签到 ,获得积分10
14秒前
渔渔完成签到 ,获得积分10
16秒前
16秒前
16秒前
Kamaru完成签到 ,获得积分10
17秒前
雪山大地发布了新的文献求助10
17秒前
pingchangxinyi完成签到 ,获得积分10
18秒前
Xu完成签到,获得积分10
19秒前
Lune7发布了新的文献求助10
23秒前
pushengxiong发布了新的文献求助10
23秒前
阳阳完成签到 ,获得积分10
23秒前
24秒前
青帝完成签到 ,获得积分10
24秒前
芭乐王子完成签到 ,获得积分10
26秒前
brilliant完成签到 ,获得积分10
28秒前
fantasy的应助被369ninja采纳,获得10
29秒前
qianhuxinyu完成签到,获得积分10
32秒前
yy完成签到,获得积分10
32秒前
boymin2015完成签到 ,获得积分10
34秒前
科研通AI6.2的应助被cherry_mm采纳,获得30
35秒前
Mia123完成签到,获得积分10
37秒前
蜘蛛侠完成签到,获得积分10
41秒前
雪山大地发布了新的文献求助10
41秒前
咚咚大王完成签到 ,获得积分10
41秒前
博士完成签到 ,获得积分10
42秒前
几几完成签到,获得积分10
43秒前
cheng完成签到 ,获得积分10
44秒前
HJJHJH的应助被科研通管家采纳,获得30
45秒前
Owen的应助被科研通管家采纳,获得10
45秒前
长泽梓完成签到 ,获得积分20
46秒前
yli130发布了新的社区帖子
46秒前
SilentLight完成签到,获得积分10
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166550
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750720
捐赠科研通 7757357
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553523
邀请新用户注册赠送积分活动 2473904